Cancer immunotherpay

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Salinomycin, Amitriptyline, Temozolomide, Berberine, Rosuvastatin and 17-DMAG (SATBRD) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 29/November/2017, 10.29 pm
Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Salinomycin, Amitriptyline, Temozolomide, Berberine, Rosuvastatin and 17-DMAG (SATBRD) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 29/November/2017, 10.29 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, David Geffen UCLA…

read more

Small molecule-based GPC2 pathway blockade enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing Shikonin, Idasanutlin, Rhamnetin, and Cisplatin [SIRC] inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 27/October/2017, 12.46 am
Small molecule-based GPC2 pathway blockade enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing Shikonin, Idasanutlin, Rhamnetin, and Cisplatin [SIRC] inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 27/October/2017, 12.46 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA shows that “Identification of…

read more

Small molecule-based GPC2 pathway blockade enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing Salinomycin, EGCG, Temozolomide, & Magnolol [SETM] inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 21/October/2017, 8.17 am
Small molecule-based GPC2 pathway blockade enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing Salinomycin, EGCG, Temozolomide, & Magnolol [SETM] inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 21/October/2017, 8.17 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA shows that “Identification of…

read more

Small molecule-based GPC2 pathway blockade enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing Ascorbate, Delta-tocotrienol, Dehydroleucodine, & Forodesine [ADDF] inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 18/October/2017, 11.27 pm
Small molecule-based GPC2 pathway blockade enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing Ascorbate, Delta-tocotrienol, Dehydroleucodine, & Forodesine [ADDF] inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 18/October/2017, 11.27 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA shows that “Identification of…

read more

Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing Mevastatin, Desipramine, EGCG, Decitabine, Biochanin A, Temozolomide (TMZ) , Cholecalciferol, PEITC, & Linalool (MDEBTCPL)  inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 04/October/2017, 11.04 pm
Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing Mevastatin, Desipramine, EGCG, Decitabine, Biochanin A, Temozolomide (TMZ) , Cholecalciferol, PEITC, & Linalool (MDEBTCPL)  inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 04/October/2017, 11.04 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands has identified CMTM6 and CMTM4 as…

read more

Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing MC44, Ganetesbib, Fluvastatin, 9cRA, PEITC, Withaferin A and Temozolomide (TMZ) (MGFRPWT) inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 16/September/2017, 06.49 am
Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing MC44, Ganetesbib, Fluvastatin, 9cRA, PEITC, Withaferin A and Temozolomide (TMZ) (MGFRPWT) inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 16/September/2017, 06.49 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands has identified CMTM6 and CMTM4 as…

read more
Start Typing